Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cellular immunogenicity after SARS-CoV-2 vaccination in older adults
2021-002363-22Phase 4Completed
- Sponsor
- National Institute for Public Health and the Environment
- Start
- May 2021
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of SARS-CoV-2 vaccine in coronavirus disease 2019 (COVID-19), sponsored by National Institute for Public Health and the Environment. Primary endpoint: Specific serum IgG antibody concentrations. Started May 2021; status: completed.
02
Drugs
SARS-CoV-2 vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-002363-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002363-22.